Rosetta Green Closes Israeli IPO, Raising $6M to Advance microRNA Programs | GenomeWeb

By Doug Macron

Rosetta Genomics announced this week that its plant biotech subsidiary Rosetta Green has gone public in Israel, raising a little more than $6 million.

The money raised in the initial public offering on the Tel Aviv Stock Exchange will allow Rosetta Green to advance its development of microRNAs for agricultural, industrial, and clean technology applications, Rosetta President and CEO Kenneth Berlin said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.